A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer (Q81604925)
Jump to navigation
Jump to search
scientific article published on 01 November 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer |
scientific article published on 01 November 2005 |
Statements
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer (English)
T G Ehlen
P J Hoskins
D Miller
T L Whiteside
C F Nicodemus
B C Schultes